Each dot is one of the 103 Pharmaceuticals and Biotechnology stocks, sized by market cap. The median Revenue Growth (1y) (TTM) is 16.3% and the median P/E 17.14. Pinned to the edge: 10 outliers on X and 4 on Y.
Quadrants split at the medians. Hover a dot for its true values; click to open the company. Outliers are more than 3× the interquartile range beyond the quartiles.
| # | Industry | ||||
|---|---|---|---|---|---|
| 1 | LLYEli Lilly | 45.5% | 46.74 | $1.36T | Pharmaceuticals |
| 2 | JNJJohnson & Johnson | 7.8% | 42.83 | $688.76B | Pharmaceuticals |
| 3 | ABBVAbbVie | 10.7% | 50.48 | $521.69B | Pharmaceuticals |
| 4 | MRKMerck | 4.9% | 148.68OUT | $364.31B | Pharmaceuticals |
| 5 | AZNAstrazeneca | 7.8% | 25.92 | $285.96B | Pharmaceuticals |
| 6 | AMGNAmgen | 8.2% | 26.83 | $251.88B | Biotechnology |
| 7 | ABTAbbott Laboratories | 10.0% | 40.05 | $187.98B | Medical Devices |
| 8 | PFEPfizer | 1.3% | 40.85 | $164.73B | Pharmaceuticals |
| 9 | VRTXVertex Pharmaceuticals | 10.5% | 34.34 | $136.55B | Biotechnology |
| 10 | BMYBristol Myers Squibb | 4.2% | 14.02 | $129.66B | Pharmaceuticals |
| 11 | GSKGsk | 82.9% | 8.11 | $108.86B | Pharmaceuticals |
| 12 | REGNRegeneron Pharmaceuticals | 18.6% | 20.17 | $97.17B | Biotechnology |
| 13 | CORCencora | 5.0% | 22.64 | $68.51B | Drug Distribution |
| 14 | ARGXArgenx Se | 61.5% | 31.35 | $59.41B | Biotechnology |
| 15 | SNYSanofi | -19.6% | 6.24 | $58.98B | Pharmaceuticals |
| 16 | IDXXIdexx Laboratories | 11.9% | 46.96 | $55.49B | Animal Health |
| 17 | TEVATeva Pharmaceutical Industries | 2.7% | 102.64 | $51.97B | Generic Drugs |
| 18 | ONCBeOne Medicines | 32.9% | 51.73 | $47.53B | Pharmaceuticals |
| 19 | GEHCGE HealthCare Technologies | 6.9% | 17.42 | $37.54B | Diagnostic Equipment |
| 20 | BIIBBiogen | 2.3% | 107.78 | $37.46B | Biotechnology |
| 21 | ALCAlcon | 8.0% | 54.90 | $36.13B | Medical Devices |
| 22 | ZTSZoetis | 0.9% | 13.76 | $34.16B | Animal Health |
| 23 | UTHRUnited Therapeutics | 1.9% | 20.51 | $25.06B | Pharmaceuticals |
| 24 | ALNYAlnylam Pharmaceuticals | 60.8% | 8.34 | $22.09B | Biotechnology |
| 25 | ZBHZimmer Biomet Holdings | 7.0% | 25.63 | $19.53B | Medical Devices |
| 26 | ASNDAscendis Pharma A | 93.8% | 16.31 | $17.07B | Biotechnology |
| 27 | NBIXNeurocrine Biosciences | 38.0% | 24.21 | $16.96B | Pharmaceuticals |
| 28 | EXELExelixis | 9.1% | 19.24 | $16.88B | Pharmaceuticals |
| 29 | KNSAKiniksa Pharmaceuticals International | 58.2% | 68.75 | $15.13B | Biotechnology |
| 30 | RDYDr Reddys Laboratories | -10.5% | 33.78 | $12.31B | Generic Drugs |
| 31 | HALOHalozyme Therapeutics | 45.0% | 23.51 | $11.42B | Biotechnology |
| 32 | BWXTBWX Technologies | 17.7% | 30.09 | $11.27B | Nuclear Equipment |
| 33 | TGTXTg Therapeutics | 68.8% | 85.63 | $9.75B | Biotechnology |
| 34 | GMEDGlobus Medical | 13.4% | 17.35 | $9.56B | Medical Devices |
| 35 | KRYSKrystal Biotech | 26.0% | 40.14 | $9.04B | Gene and Cell Therapy |
| 36 | CHWYChewy | 5.9% | 33.42 | $9.04B | Packaged Foods |
| 37 | PTGXProtagonist Therapeutics | 163.7%OUT | 25.39 | $8.54B | Biotechnology |
| 38 | CORTCorcept Therapeutics | 30.0% | 48.81 | $7.98B | Pharmaceuticals |
| 39 | AMRXAmneal Pharmaceuticals | 8.9% | 53.85 | $7.45B | Generic Drugs |
| 40 | LGNDLigand Pharmaceuticals | 1.0% | 119.78 | $6.18B | Biotechnology |
| 41 | FMSFresenius Medical Care AG | -49.1% | 6.71 | $6.16B | Healthcare Services |
| 42 | EWTXEdgewise Therapeutics | 36.6% | 4.95 | $5.03B | Pharmaceuticals |
| 43 | OGNOrganon | -3.2% | 17.14 | $3.65B | Pharmaceuticals |
| 44 | ARQTArcutis Biotherapeutics | 60.0% | 123.78 | $3.56B | Biotechnology |
| 45 | SUPNSupernus | 16.3% | 7.79 | $3.51B | Pharmaceuticals |
| 46 | TAKTakeda Pharmaceutical | -35.4% | 10.69 | $3.41B | Pharmaceuticals |
| 47 | GMABGenmab A | 22.5% | 3.81 | $3.30B | Biotechnology |
| 48 | ACADAcadia Pharmaceuticals | 14.8% | 8.93 | $3.24B | Pharmaceuticals |
| 49 | ADMAAdma Biologics | 6.3% | 16.78 | $3.05B | Biotechnology |
| 50 | VCELVericel | 25.3% | 87.53 | $2.91B | Gene and Cell Therapy |
| 51 | LKFTLakefront Biotherapeutics | 240.8%OUT | 2.40 | $2.24B | Biotechnology |
| 52 | AUPHAurinia Pharmaceuticals | 21.0% | 6.68 | $2.11B | Pharmaceuticals |
| 53 | HRMYHarmony Biosciences Holdings | 19.8% | 11.04 | $1.98B | Pharmaceuticals |
| 54 | ZYMEZymeworks | 97.8% | 43.39 | $1.87B | Biotechnology |
| 55 | ETONEton Pharmaceuticals | 100.6% | 36.75 | $1.84B | Pharmaceuticals |
| 56 | ANIPAni Pharmaceuticals | 25.9% | 12.97 | $1.71B | Generic Drugs |
| 57 | NRIXNurix Therapeutics | 738.8%OUT | 5.86 | $1.69B | Biotechnology |
| 58 | PGENPrecigen | 2,388%OUT | 66.64 | $1.63B | Gene and Cell Therapy |
| 59 | JAZZJazz Pharmaceuticals | 13.5% | 7.59 | $1.55B | Pharmaceuticals |
| 60 | PAHCPhibro Animal Health | 10.1% | 14.21 | $1.46B | Animal Health |
| 61 | PCRXPacira BioSciences | 3.7% | 38.52 | $1.45B | Pharmaceuticals |
| 62 | ANABAnaptysbio | 41.9% | 87.82 | $1.38B | Biotechnology |
| 63 | INVAInnoviva | 12.8% | 7.09 | $1.36B | Pharmaceuticals |
| 64 | AMPHAmphastar Pharmaceuticals | 3.1% | 12.64 | $1.25B | Generic Drugs |
| 65 | MGTXMeiraGTx Holdings | 1,366%OUT | 11.36 | $896.15M | Gene and Cell Therapy |
| 66 | PHARPharming | -6.5% | 35.82 | $884.12M | Biotechnology |
| 67 | RIGLRigel Pharmaceuticals | 2.2% | 2.71 | $837.18M | Biotechnology |
| 68 | ABUSArbutus Biopharma | 1,143%OUT | 3.70 | $812.59M | Biotechnology |
| 69 | IRWDIronwood Pharmaceuticals | 18.1% | 5.32 | $799.61M | Biotechnology |
| 70 | COLLCollegium Pharmaceutical | 7.7% | 21.05 | $786.73M | Pharmaceuticals |
| 71 | DCTHDelcath Systems | 38.1% | 111.41 | $714.55M | Medical Devices |
| 72 | ZVRAZevra Therapeutics | 75.2% | 6.91 | $539.71M | Pharmaceuticals |
| 73 | KMDAKamada | 12.6% | 19.04 | $466.68M | Biotechnology |
| 74 | AGENAgenus | 25.4% | 14.31 | $421.62M | Biotechnology |
| 75 | FENCFennec Pharmaceuticals | 71.1% | 201.28OUT | $409.20M | Generic Drugs |
| 76 | PBYIPuma Biotechnology | 9.4% | 16.86 | $401.70M | Biotechnology |
| 77 | CRMDCorMedix | 92.5% | 5.90 | $370.36M | Pharmaceuticals |
| 78 | ELTPElite Pharmaceuticals | 17.8% | 5.90 | $355.46M | Generic Drugs |
| 79 | ALECAlector | 151.2% | 6.86 | $285.18M | Biotechnology |
| 80 | QTTBQ32 Bio | 75.7% | 120.37 | $260.36M | Biotechnology |
| 81 | INCYIncyte | 24.9% | 0.61 | $246.78M | Pharmaceuticals |
| 82 | PLXProtalix BioTherapeutics | 37.0% | 11.87 | $245.74M | Biotechnology |
| 83 | OMEROmeros | 1,532%OUT | 2.25 | $236.99M | Biotechnology |
| 84 | CGENCompugen | 1,000.0%OUT | 5.39 | $198.56M | Biotechnology |
| 85 | SIGASiga Technologies | -69.6% | 13.22 | $196.88M | Pharmaceuticals |
| 86 | FHTXFoghorn Therapeutics | 357.3%OUT | 15.73 | $124.12M | Biotechnology |
| 87 | ICCCImmucell | 19.6% | 51.96 | $97.73M | Animal Health |
| 88 | CPIXCumberland Pharmaceuticals | 10.7% | 1.28 | $88.16M | Pharmaceuticals |
| 89 | VXRTVaxart | 22.3% | 3.01 | $87.73M | Biotechnology |
| 90 | RLYBRallybio | -35.6% | 3.35 | $83.84M | Biotechnology |
| 91 | FBIOFortress Biotech | 12.3% | 0.65 | $62.62M | Biotechnology |
| 92 | ATNMActinium Pharmaceuticals | 936.3%OUT | 4.55 | $51.56M | Biotechnology |
| 93 | IBOImpact Biomedical | 22.6% | 27.21 | $43.92M | Biotechnology |
| 94 | UGUnited Guardian | 23.6% | 12.43 | $38.87M | Pharmaceuticals |
| 95 | ETSTEarth Science Tech | 1.1% | 6.89 | $25.78M | Generic Drugs |
| 96 | TXMDTherapeuticsMD | 33.9% | 177.40OUT | $21.64M | Pharmaceuticals |
| 97 | CSCIFCOSCIENS Biopharma | -11.6% | 4.52 | $18.43M | Specialty Chemicals |
| 98 | PLURPluri | 10.0% | 0.00 | $15.09M | Gene and Cell Therapy |
| 99 | KYNBKyntra Bio | 3.0% | 0.08 | $13.93M | Biotechnology |
| 100 | INNPFInnocan Pharma | -9.6% | 481.28OUT | $5.78M | Pharmaceuticals |
Among Pharmaceuticals and Biotechnology stocks, the largest companies growing revenue faster than the median (16.3%) while trading below the median P/E (17.14) are Gsk (GSK), Alnylam Pharmaceuticals (ALNY), Ascendis Pharma A (ASND), Edgewise Therapeutics (EWTX) and Supernus (SUPN). A low multiple next to fast growth can be an opportunity or a sign the market doubts the growth will last.
The largest companies with a P/E above the median and revenue growth below it are Johnson & Johnson (JNJ), AbbVie (ABBV), Merck (MRK), Astrazeneca (AZN) and Amgen (AMGN).
The median P/E across the 103 Pharmaceuticals and Biotechnology stocks plotted is 17.14, with the middle half between 6.79 and 40.49.
The median is 16.3%, with the middle half between 5.4% and 43.4%.
The rank correlation (Spearman) is 0.01, a no meaningful positive relationship: knowing one tells you little about the other.
A company whose value lies more than three interquartile ranges beyond the first or third quartile is treated as an outlier. By default it stays on the chart, pinned to the edge as an open marker, and its true value is shown in the tooltip and the table. In this view 10 companies are outliers on Revenue Growth (1y) (TTM) and 4 on P/E. You can switch to percentile clamping, exclude outliers, or plot raw values on a log scale.
Metrics from Business Quant's screener: trailing-twelve-month figures from SEC filings and multiples on the latest close. A company appears once even when it lists more than one share class. A company with a secondary business line in this industry group is included unless you choose primary industry only. Nothing on this page is investment advice.